Exhibit 99.2
 
ADMA Biologics, Inc. and Subsidiary
(A Development Stage Enterprise)
 
Index
 
Condensed Consolidated Balance Sheets
September 30, 2011 (unaudited) and December 31, 2010
F-2
   
Unaudited Condensed Consolidated Statements of Operations
Nine Months Ended September 30, 2011 and 2010 and the Period from June 24, 2004 (Date of Inception)
through September 30, 2011
F-3
   
Unaudited Condensed Consolidated Statement of Changes in Stockholders’ Deficiency
Nine Months Ended September 30, 2011
F-4
   
Unaudited Condensed Consolidated Statements of Cash Flows
Nine Months Ended September 30, 2011 and 2010 and the Period from June 24, 2004 (Date of Inception)
through September 30, 2011
F-5
   
Notes to Condensed Consolidated Financial Statements
F-6
 
 
F-1

 
 
ADMA BIOLOGICS, INC. AND SUBSIDIARY
(a development stage enterprise)
Condensed Consolidated Balance Sheets
as of September 30, 2011 (Unaudited) and December 31, 2010
 
ASSETS
           
   
September 30,
   
December 31,
 
Current Assets
 
2011
   
2010
 
             
Cash and Cash Equivalents
  $ 4,198     $ 228,971  
Inventories
    974,436       3,390,455  
Prepaid Expenses
    100,285       64,781  
Total Current Assets
    1,078,919       3,684,207  
                 
Property and Equipment at Cost, Net
    914,998       1,081,159  
                 
Other Assets
               
                 
Restricted Cash
    336,963       426,963  
Deposits
    12,577       12,577  
Total Other Assets
    349,540       439,540  
                 
Total Assets
  $ 2,343,457     $ 5,204,906  
                 
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
               
                 
Current Liabilities
               
                 
Accounts Payable
  $ 934,582     $ 842,178  
Accrued Expenses
    282,104       242,398  
Accrued Interest
    1,225,474       650,301  
Current Portion of Leasehold Improvement Loan
    9,515       9,669  
Notes Payable - Related Parties (Net of debt discount of $184,185 in 2010)
    8,500,000       7,115,815  
Total Current Liabilities
    10,951,675       8,860,361  
                 
Deferred Rent Liability
    155,333       171,975  
Leasehold Improvement Loan
    92,192       99,262  
                 
Total Liabilities
    11,199,200       9,131,598  
                 
Commitments and Contingencies
               
                 
Stockholders' Deficiency
               
                 
Preferred Stock - $.001 par value, 3,400,000 shares authorized,
               
3,386,454 shares issued and outstanding with a liquidation preference of $21,114,465 and $19,924,465 at December 31, 2010 and 2009, respectively
    3,386       3,386  
Common Stock - $.001 par value, 6,500,000 shares authorized,
               
351,535 shares issued and outstanding
    352       352  
Additional Paid-In Capital
    19,993,748       19,974,125  
Deficit Accumulated During the Development Stage
    (28,853,229 )     (23,904,555 )
Total Stockholders' Deficiency
    (8,855,743 )     (3,926,692 )
Total Liabilities and Stockholders' Deficiency
  $ 2,343,457     $ 5,204,906  
 
See notes to condensed consolidated financial statements.
 
 
F-2

 
 
ADMA BIOLOGICS, INC. AND SUBSIDIARY
(a development stage enterprise)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the Nine Months Ended September 30, 2011 and 2010 (Unaudited)
and the Period from June 24, 2004 (Date of Inception) through September 30, 2011
 
   
Nine Months Ended September 30,
   
Nine Months Ended September 30,
   
Cumulative Period From June 24, 2004 (Inception) to September 30,
 
   
2011
   
2010
   
2011
 
Costs and expenses
                 
                   
Research and development expenses
  $ 443,188     $ 1,652,477     $ 14,375,870  
                         
Loss on sale of research and development inventory
    1,934,630       -       1,934,630  
                         
Plasma center operating expenses
    1,191,243       1,484,802       5,993,600  
                         
General and administrative expenses
    932,248       1,138,921       6,271,326  
                         
Total Operating Expenses
                       
and Loss from Operations
    4,501,309       4,276,200       28,575,426  
                         
Other income (expense)
                       
                         
Other income
    -       -       244,479  
Interest income
    1,212       9,473       732,414  
Interest expense
    (769,342 )     (448,337 )     (1,575,461 )
                         
Total Other Income (Expense)
    (768,130 )     (438,864 )     (598,568 )
                         
                         
Loss before income taxes
    (5,269,439 )     (4,715,064 )     (29,173,994 )
                         
Income tax benefit
    320,765       -       320,765  
                         
Net Loss
  $ (4,948,674 )   $ (4,715,064 )   $ (28,853,229 )
                         
Net Loss per Share -
                       
Basic and Diluted
  $ (14.08 )   $ (13.41 )        
                         
Weighted Average Number of
                       
Shares Outstanding - Basic and Diluted
    351,535       351,535          
 
See notes to condensed consolidated financial statements.
 
 
F-3

 
 
ADMA BIOLOGICS, INC. AND SUBSIDIARY
(a development stage enterprise)
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIENCY
For the Nine Months Ended September 30, 2011 (Unaudited)
 
                                 
Deficit
       
                                 
Accumulated
       
   
Preferred Stock
   
Common Stock
   
Additional
   
During the
       
                           
Paid-in
   
Development
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Stage
   
Total
 
                                           
Balance - January 1, 2011
    3,386,454     $ 3,386       351,535     $ 352     $ 19,974,125     $ (23,904,555 )   $ (3,926,692 )
                                                         
Stock based compensation
    -       -       -       -       19,623       -       19,623  
                                                         
Net loss for the nine months ended September 30, 2011
    -       -       -       -       -       (4,948,674 )     (4,948,674 )
      3,386,454     $ 3,386       351,535     $ 352     $ 19,993,748     $ (28,853,229 )   $ (8,855,743 )
 
See notes to condensed consolidated financial statements.
 
 
F-4

 
 
ADMA BIOLOGICS, INC. AND SUBSIDIARY
(a development stage enterprise)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Nine Months Ended September 30, 2011 and 2010
and the Period from June 24, 2004 (Date of Inception) through September 30, 2011 (Unaudited)
 
   
Nine Months Ended September 30,
   
Nine Months Ended September 30,
   
Cumulative Period From June 24, 2004 (Inception) to September 30,
 
   
2011
   
2010
   
2011
 
Cash Flows from Operating Activities
                 
Net Loss
  $ (4,948,674 )   $ (4,715,064 )   $ (28,853,229 )
Adjustments to reconcile net loss
                       
to net cash used in operating activities:
                       
Depreciation and Amortization
    166,161       139,250       633,874  
Stock Based Compensation
    19,623       26,107       137,721  
Amortization of Debt Discount
    184,185       48,848       316,847  
Loss on Sale of Research and Development Inventory
    1,934,630               1,934,630  
Changes in operating assets and liabilities
                       
(Increase) Decrease in Inventories
    481,389       (193,502 )     (2,909,066 )
Increase in Prepaid Expenses
    (35,504 )     (8,128 )     (100,285 )
(Increase) Decrease in Other Assets
    90,000       -       (349,540 )
Increase in Accounts Payable
    92,404       90,407       934,582  
Increase in Accrued Expenses
    39,706       9,838       282,104  
Increase in Accrued Interest
    575,173       391,611       1,225,474  
Increase (Decrease) in Deferred Rent Liability
    (16,642 )     (7,731 )     155,333  
                         
Net Cash Used in Operating Activities
    (1,417,549 )     (4,218,364 )     (26,591,555 )
                         
Cash Flows from Investing Activities
                       
Purchase of Investments
    -       -       (5,029,990 )
Proceeds from Maturity of Investments
    -       -       5,029,990  
Purchase of Equipment
    -       (1,189 )     (1,548,872 )
                         
Net Cash Used in Investing Activities
    -       (1,189 )     (1,548,872 )
                         
Cash Flows from Financing Activities
                       
Proceeds from sale of Series A Convertible preferred stock
    -       -       17,000,000  
Cash contributed by stockholder
    -       -       2,542,918  
Proceeds from Lease Improvement Loan
    -       -       125,980  
Proceeds from Notes Payable
    1,200,000       1,800,000       8,500,000  
Payments on Leasehold Improvement Loan
    (7,224 )     (6,604 )     (24,273 )
                         
Net Cash Provided by Financing Activities
    1,192,776       1,793,396       28,144,625  
                         
Net Increase (Decrease) in Cash and Cash Equivalents
    (224,773 )     (2,426,157 )     4,198  
                         
Cash and Cash Equivalents, Beginning of Period
    228,971       2,754,058       -  
                         
Cash and Cash Equivalents, End of Period
  $ 4,198     $ 327,901     $ 4,198  
                         
SUPPLEMENTAL DISCLOSURES:
                       
                         
Interest paid
  $ 9,984     $ 7,878     $ 33,140  
 
See notes to condensed consolidated financial statements.
 
 
F-5

 
 
ADMA BIOLOGICS, INC. AND SUBSIDIARY
(a development stage enterprise)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
SEPTEMBER 30, 2011 AND 2010
 
1.
ORGANIZATION AND BUSINESS
 
ADMA Biologics, Inc. (the “Company”), a development stage enterprise, was incorporated on July 9, 2007, in the State of Delaware.  On July 16, 2007, the Company, formerly named ADMA Temp, Inc., entered into an agreement and plan of merger (the “Agreement”) with ADMA Biologics, Inc. (“ADMA NJ”), which was incorporated on June 24, 2004 in the State of New Jersey.  ADMA NJ was a development stage company engaged in developing and commercializing human plasma-derived products, with its first and second product being a human immunoglobulin.  As of January 2008, one of these products has been cleared by the Food and Drug Administration (FDA) to commence Phase II clinical trials.
 
Pursuant to the Agreement, the Company acquired 100% of the outstanding capital stock of ADMA NJ.  In connection with the merger, the Company subsequently changed its name to ADMA Biologics, Inc. and increased its authorized common stock to 6,500,000 shares and its authorized preferred stock to 3,400,000 shares. Under the terms of the Agreement, the stockholders of ADMA NJ exchanged all of their issued and outstanding shares of common stock for 351,535 shares of the Company’s common stock (the “Exchange”).
 
The 351,535 shares of common stock represented 100% of the ownership interests in the Company following the merger. The Exchange resulted in the stockholders of ADMA NJ having control of the Company, representing a recapitalization of the Company, or a “reverse merger” rather than a business combination.
 
In connection therewith, the Company’s historical capital accounts were retroactively adjusted to reflect the equivalent number of shares issued by the Company in the Exchange while ADMA NJ’s historical accumulated deficit was carried forward. The statement of operations reflects the activities of ADMA NJ from the commencement of its operations on June 24, 2004.
 
On April 3, 2008, the Company formed a wholly-owned subsidiary, ADMA BioCenters Georgia, Inc., for the purpose of operating plasma collection centers.  The subsidiary is a Delaware corporation operating in Georgia.
 
As a development stage enterprise, the Company's primary efforts are devoted to conducting research and development of human plasma-derived products for the treatment of specific disease states. As the Company has limited capital resources and has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future, the Company has needed to raise capital from the sales of its securities to sustain operations. As of September 30, 2011, the Company had minimal cash. Management believes that cash on hand as of September 30, 2011 is not sufficient to fund operations for the next twelve months. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The Company will be required to obtain loans or raise additional funds to meet long-term obligations and continue operations. There can be no assurance that such funds, if available at all, can be obtained on terms acceptable to the Company.
 
In addition to the normal risks associated with a new business venture, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.
 
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
The following comprises the Company's significant accounting policies:
 
Basis of presentation and principles of consolidation
 
The accompanying consolidated financial statements include the accounts of ADMA Biologics, Inc. and its wholly-owned subsidiary ADMA BioCenters Georgia, Inc. All significant intercompany transactions and balances have been eliminated in consolidation. The Company's financial statements are presented as statements of a development stage enterprise. The Company's primary operations since inception have been devoted to the research and development of human plasma-derived products. No operating revenue has been generated. As a result, the financial statements are presented in accordance with Accounting and Reporting by Development Stage Enterprises.
 
 
F-6

 
 
The consolidated financial statements for the interim periods included herein are unaudited; however, they contain all adjustments (consisting of only normal recurring adjustments) which in the opinion of management are necessary to present fairly the consolidated financial position of the Company as of September 30, 2011 and their results of operations and cash flows for the nine months ended September 30, 2011 and 2010.  The results of operations for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.  These interim financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included elsewhere in this Form 8-K.
 
The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, in accordance with the rules and regulations of the Securities and Exchange Commission for interim reporting.  Pursuant to such rules and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed of omitted.
 
Cash and cash equivalents
 
The Company considers all highly-liquid instruments purchased with a maturity of three months or less to be cash equivalents.
 
Inventories
 
Plasma inventories are carried at the lower of cost or market value determined on the first-in, first-out method.  Physical inventories are conducted at the end of each year and perpetual records are adjusted accordingly.  Once the plasma is processed to a finished good for ongoing trials it is then expensed to research and development. Inventory at September 30, 2011 and December 31, 2010 consists of raw materials.  Approximately 9,000 liters of plasma that had been purchased for use in research and development were sold in 2011, and the Company recorded a loss of $1,934,630.
 
Research and development costs
 
The Company expenses all research and development costs as incurred including plasma and equipment for which there is no alternative future use. Such expenses include licensing fees and costs associated with planning and conducting clinical trials.
 
Use of estimates
 
The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.  Significant estimates include valuation of inventory, assumptions used in the fair value of stock-based compensation, and the allowance for the valuation of future tax benefits.
 
Concentration of credit risk
 
Financial instruments which potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents.
 
Property and equipment
 
Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset's estimated useful life, which is five to ten years.  Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.
 
Income taxes
 
From June 24, 2004 to July 16, 2007, the Company elected to be taxed as an S corporation for both Federal and State income tax reporting purposes.  Accordingly, the taxable income or loss related to that period was includable in the personal income tax returns of the stockholders.
 
Effective July 16, 2007, the Company was merged into a C corporation and adopted guidance issued for Accounting for Income Taxes which requires that the Company recognize deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred income tax assets if it is more likely than not that these deferred income tax assets will not be realized.
 
 
F-7

 
 
The Company adopted the new accounting guidance for uncertainty in income taxes on January 1, 2007. The adoption of that guidance did not result in the recognition of any unrecognized tax benefits and the Company has no unrecognized tax benefits at September 30, 2011 and December 31, 2010. The Company's U.S. Federal and state income tax returns prior to fiscal year 2007 are closed and management continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.
 
The Company will recognize interest and penalties associated with tax matters as income tax expense.
 
Earnings (Loss) Per Share
 
Net loss per share is determined in accordance with the two-class method.  This method is used for computing basic net loss per share when companies have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of the Company.  Under the two-class method, net loss is allocated between common shares and other participating securities based on their participation rights in both distributed and undistributed earnings.  The Company’s Series A convertible preferred stock are participating securities, since the stockholders are entitled to share in dividends declared by the board of directors with the common stock based on their equivalent common shares.
 
Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period.  Because the holders of the Series A convertible preferred stock are not contractually required to share in the Company’s losses, in applying the two-class method to compute basic net loss per common share no allocation to preferred stock was made for the nine months ended September 30, 2011 and 2010.
 
Diluted net loss per share is calculated by dividing net loss attributable to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of common stock and dilutive common stock outstanding during the period.  Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options and a warrant (using the treasury stock method) and the conversion of the shares of Series A convertible preferred stock (using the more dilutive of the (a) as converted method or (b) the two–class method).  Potential common shares in the diluted net loss per share computation are excluded to the extent that they would be anti-dilutive.  No potentially dilutive securities are included in the computation of any diluted per share amounts as the Company reported a net loss for all periods presented.  Potentially dilutive securities that would be issued upon conversion of convertible notes, conversion of Series A convertible preferred stock, and the exercise of outstanding warrants and stock options, were 1.9 million and 1.7 million as of September 30, 2011 and 2010, respectively.
 
Stock-based compensation
 
The Company follows recognized accounting guidance which requires all stock-based payments, including grants of stock options, to be recognized in the Statement of Operations as compensation expense, based on their fair values on the grant date. The estimated fair value of options granted under the Company’s 2007 Employee Stock Option Plan (“Plan”) are recognized as compensation expense over the option-vesting period.
 
During the nine months ended September 30, 2011 and 2010, the Company recorded stock-based compensation expense to employees and a consultant of $19,623 and $26,107, respectively.
 
The fair value of employee options granted was determined on the date of grant using the Black-Scholes model. The Black-Scholes option valuation model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. The Company's employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. Because there is no public market for the Company's stock and very little historical experience with the Company's stock options, a small similar publicly traded company was used for comparison and expectations as to assumptions required for fair value computation using the Black-Scholes methodology. Accordingly, the Company's stock price volatility is expected to be 72% and the expected term of options outstanding is 6.25 years. For options granted in 2008, the Company used a risk-free interest rate of 3.364% which corresponded to the expected term on the date of grant for each option contract. The Company's dividend yield has been assumed at 0% as the Company has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.
 
Guidance for stock-based compensation requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company currently estimates there will be no forfeitures of options.
 
 
F-8

 
 
Fair value of financial instruments
 
The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, and accounts payable are shown at cost which approximates fair value due to the short-term nature of these instruments.
 
Subsequent events
 
The Company evaluated subsequent events through February 13, 2012, the date the financial statements were available to be issued.
 
3.
LEASEHOLD IMPROVEMENT LOAN
 
In connection with the lease of commercial real estate by the Company’s wholly owned subsidiary for the operation of the plasma collection center, the Company borrowed $125,980 from the lessor to pay for leasehold improvement costs in excess of the allowance provided for in the lease agreement.  The loan bears interest at 9% and is payable in 120 monthly installments of $1,596 maturing December 31, 2019.  Principal maturities under the loan are as follows:
 
2011 (remaining period)   $ 1,671  
2012
    10,577  
2013
    11,569  
2014
    12,654  
2015
    13,841  
2016
    15,139  
Thereafter
    36,256  
Total
  $ 101,707  
 
4.
NOTES PAYABLE TO SIGNIFICANT STOCKHOLDERS
 
The Company has issued senior secured convertible promissory notes to significant stockholders pursuant to the terms of Note Purchase Agreements.  The outstanding principal and interest under the notes are due and payable upon the earliest to occur of:  (i) December 31, 2011 (as amended); (ii) the date on which the Company consummates a preferred stock financing in which the gross proceeds to the Company total at least $10,000,000 (“Qualified Financing” as defined in the Notes); and (iii) the occurrence of an Event of Default (as defined in the Notes), the first of these three events to occur referred to as the “Maturity Date”.  Interest accrues on the outstanding principal at the stated rate and is payable on the Maturity Date.
 
Issue Date
 
Principal Amount
   
Interest Rate
   
Conversion Price
   
Convertible Into
   
Warrants Issued
 
Aug–09
  $ 2,500,000       9 %   $ 15.24941    
Preferred Series A-1
       
Dec-09
    2,500,000       9 %   $ 15.24941    
Preferred Series A-1
       
Jun-10
    1,800,000       12 %   $ 13.55240    
Preferred Series A-2
      52,730  
Dec-10
    500,000       10 %   $ 13.55240    
Preferred Series A-2
         
Feb-11
    300,000       10 %   $ 13.55240    
Preferred Series A-2
         
May-11
    250,000       10 %   $ 13.55240    
Preferred Series A-2
         
Jun-11
    300,000       10 %   $ 13.55240    
Preferred Series A-2
         
Aug-11
    250,000       10 %             N/A       4,612  
Sep-11
    100,000       18 %             N/A          
    $ 8,500,000                               57,342  
 
If all or any of the principal and accrued interest thereon remains outstanding prior to the date of a Qualified Financing, those amounts shall automatically convert into shares of the Company’s preferred stock at the lower of (a) the price per share paid by investors in the Qualified Financing or (b) the stated Conversion Price.
 
Any principal and accrued interest thereon that remains outstanding will convert into preferred shares at the stated conversion price if immediately prior to the Maturity Date, a Qualified Financing has not occurred and the Company does not have sufficient cash on hand to repay the outstanding balance in full.  The Series A-1 and A-2 Preferred Stock shall have the same rights and privileges as the Company’s Series A Preferred Stock and shall be senior to the Series A Preferred Stock in liquidation preference.
 
If the principal amounts due under these notes are repaid on the Maturity Date, the payees have the option to convert all of the accrued interest into shares of Series A Preferred Stock determined by dividing the interest by the Conversion Price.
 
In the Event of a Default, the interest rate stated on the notes shall be increased by three percent (3%) per annum. The Notes are collateralized by all of the assets of the Company.
 
 
F-9

 
 
In connection with the issuance of these Notes, the Company issued common stock purchase warrants expiring ten years from date of issue to existing common and preferred stockholders at an exercise price of $.01 per share. Such warrants vested immediately and can be exercised at any time up to the expiration date.  No warrants were exercised in the nine months ended September 30, 2011.
 
The following table summarizes information about warrants outstanding as of September 30, 2011:
 
   
Number Of Warrants
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term
Balance Outstanding - December 31, 2010
 
52,730
 
$0.07
 
9.5 years
Issued
 
4,612
 
$0.07
 
9.9 years
             
Balance Outstanding - September 30, 2011
 
57,342
 
$0.07
 
8.85 years
             
Exercisable - September 30, 2011
 
57,342
 
$0.07
 
8.85 years
 
The Company issued promissory notes which are not convertible to significant stockholders pursuant to the terms of Note Purchase Agreements.  The outstanding principal and interest under the notes are due and payable upon the earliest to occur of: (i) December 31, 2011; (ii) the occurrence of a prepayment event (as defined in the Notes) or (iii) the occurrence of an Event of Default (as defined in the Notes), the first of these three events to occur referred to as the “Maturity Date”.
 
In October 2011, the Company received an additional $100,000 from the issuance of nonconvertible notes to stockholders with a stated interest rate of 18% and a December 31, 2011 maturity date.  A total of $200,000 in loans were repaid in October 2011 with accrued interest.
 
5.
STOCKHOLDERS’ EQUITY
 
The Company was originally organized as an S corporation and issued 15 shares of stock at a par value of $.01 each. On July 16, 2007, the Company merged into a C corporation and, concurrent with this election, each of the shares of stock of the terminating S corporation converted into 23,435.67 shares of common stock of the C corporation, resulting in a total of 351,535 shares outstanding. Since the shareholders of the S corporation became the majority shareholders of the C corporation, this was accounted for as a reverse merger.  Accordingly, the pre-merger financial statements of the S corporation have become the historical financial statements of the C corporation.
 
Upon conversion of the Company from an S corporation to a C corporation, the Company increased its authorized common stock to 6,500,000 shares with a par value of $.001 per share and authorized 3,400,000 shares of Series A preferred (Series A shares), with a par value of $.001 per share. On July 17, 2007, the Company completed a private placement and raised gross proceeds of $17,000,000 from the sale of 3,386,454 Series A convertible preferred shares at a sale price of $5.02 per share.
 
The Series A Preferred Shares have the following rights and preferences:
 
Dividends
 
From and after the date of their issuance, dividends at the rate per annum of $0.3514 per share shall accrue on Series A Preferred shares.  The Company is under no obligation to pay such accruing dividends.  However, dividends on the Preferred Shares shall be cumulative from the date of issuance and shall be paid before any dividends on shares of any other class of stock of the Company.  No such dividends were declared prior to December 31, 2010.  As of September 30, 2011 and December 31, 2010, $5,007,781 and $4,117,726, respectively, in dividends had accumulated on the Series A shares.
 
Conversion
 
The holders of the Series A Preferred Shares have the right to convert their shares to common stock at any time at an initial conversion price of $34.14 per share.  In certain situations, the Preferred Shares are protected from dilution by future issuances of common stock at less than the Series A Preferred Share conversion price. At September 30, 2011, the conversion price was $24.55 per share under these anti-dilution provisions.
 
The Company is required, at all times, to reserve a sufficient number of shares of common stock to effect the conversion of all outstanding shares of preferred stock.
 
 
F-10

 
 
Liquidation preference
 
Upon liquidation or dissolution of the Company, the holders of the Series A shares are entitled to be paid an amount per share equal to the Series A Original Issue Price ($5.02 per share) plus the cumulative unpaid dividends and any other dividends declared but unpaid.
 
Voting
 
The stockholders of the Series A Preferred Shares vote together with all other classes of stock as a single class on matters presented to the stockholders of the Company. Each holder of Series A Preferred Shares is entitled to a number of votes (one vote) equal to the number of whole shares of common stock into which the Series A Preferred Shares of such holder are convertible as of the record date for determining stockholders to vote on such matters, except with respect to certain corporate actions, which require a fifty percent (50%) approval of the then outstanding Series A Preferred Shares. The holders of record of the Series A shares, as a separate class, are entitled to elect two directors of the five-member Board of the Company.  One of the two “Series A Directors” shall serve as Chairman of the Board.  The holders of record of the common stock are also entitled to elect two directors.
 
6.
RELATED PARTY TRANSACTIONS
 
The Company leases an office building and equipment from an entity owned by related parties on a month-to-month basis.  Rent expense amounted to $72,333 for each of the nine months ended September 30, 2011 and 2010.
 
The Company maintains deposits and other accounts at a bank which is less than 5%-owned by related parties and where a stockholder is a member of the Board of Directors of the bank.
 
The Company owes $8,500,000 to existing common and preferred stockholders under senior secured convertible promissory notes and nonconvertible promissory notes at September 30, 2011.  Interest in the amount of $1,225,474 and $650,301 has been accrued on these notes as of September 30, 2011 and December 31, 2010, respectively.  Subsequent to September 30, 2011, there were additional borrowings of $100,000 from the Company’s existing common and preferred stockholders and the Company repaid $200,000 of borrowings with interest.
 
7.
COMMITMENTS AND CONTINGENCIES
 
Lease commitments
 
Effective June 1, 2008, the Company entered into a 10-year lease for a Georgia warehouse building, commencing October 1, 2008. The lease provides for annual rent increases and renewal options at market rent.  Rent expense under this lease was $108,000 and $110,736 for the nine months ended September 30, 2011 and 2010, respectively.
 
Future minimum lease payments for each of the five years ending December 31 and thereafter are as follows:
 
2011 (remaining period)
  $ 37,827  
2012
    152,247  
2013
    156,058  
2014
    159,995  
2015
    164,026  
Thereafter
    471,985  
    $ 1,142,138  
 
Irrevocable letter of credit
 
On May 27, 2008, the Company established a $426,963 Standby Letter of Credit in favor of a landlord to guarantee payment under a building lease. The landlord granted a temporary reduction of $90,000 in the amount of the required letter of credit. This reduction is valid until the Company receives FDA license for its plasma collection center in Georgia and begins to receive proceeds from the sale of plasma collected from the center.  This license was granted by the FDA in August 2011 and the company is in the process of restoring the letter of credit when sale proceeds are received.  The entire amount under this letter of credit is maintained in a restricted cash account as of September 30, 2011 and December 31, 2010.  The letter of credit expires on September 30, 2018.
 
 
F-11

 
 
8.
INCOME TAXES
 
In January 2011, the Company received approximately $321,000 from the sale of net operating loss and research and development credit carryforwards under the NJ EDA Technology Business Tax Certificate Transfer Program.
 

9.           SUBSEQUENT EVENTS

In December 2011, the corporate charter was amended to increase the authorized capital from 6,500,000 to 16,800,000 common shares and from 3,400,000 to 8,221,678 preferred shares.

Subsequent to September 30, 2011, we issued additional notes to significant stockholders and raised $300,000, and notes in the aggregate principal amount of $400,000 were repaid.

On December 22, 2011, $8,150,000 of notes payable to significant stockholders plus accrued interest were converted to Series A Preferred Stock at a conversion rate of $13.5224 per share resulting in the issuance of 4,835,224 additional shares of Series A Preferred Stock. The note holders also exercised 57,342 warrants in a cashless transaction for 57,054 shares of common stock and cancelled warrants for an additional 586 shares of common stock. The due date on all remaining notes payable to significant stockholders was extended from December 31, 2011 to March 31, 2012.

In January 2012, the Company received $617,615 in net proceeds from the sale of NJ net operating losses through the NJ EDA Technology Business Tax Certificate Transfer Program.

On February 13, 2012, in connection with, and immediately prior to the closing of the Merger (as defined below), the Company completed a private placement (the “PIPE”) of 1,828,128 shares of the Company’s common stock at a price per share of $9.60 to accredited investors, for gross proceeds to the Company of $17,550,029 pursuant to a securities purchase agreement (the “Securities Purchase Agreement”).    In lieu of repayment of senior secured promissory notes in the aggregate principal amount of $250,000 (plus $12,740 in accrued interest), the aggregate amount of unpaid principal and interest on the notes was invested by the holders of such notes in the PIPE in exchange for shares of the Company’s common stock.  The net cash proceeds from the PIPE, after the payment of all expenses related to the PIPE and the Merger, are approximately $15.2 million, not including in such proceeds the senior secured promissory notes that were satisfied in exchange for shares of the Company’s common stock in the PIPE.
 
 
F-12

 
 
Pursuant to the terms of the Securities Purchase Agreement, for a period ending on the earlier to occur of (a) 18 months following the closing of the PIPE or (b) such date that R&R Acquisition VI, Inc., a Delaware corporation (“ParentCo”) has sold in one or more transactions (other than exempt issuances as defined in the agreement) securities having an aggregate purchase price of at least $5 million, if ParentCo sells any Common Stock or Common Stock equivalents for a price less than $9.60 (a “Dilutive Issuance”), each PIPE investor will be given the right to subscribe, for $0.01 per share, for such number of additional shares of Common Stock equal to (x) the total subscription amount paid by the investor in the PIPE divided by the price per share of Common Stock paid (or payable per share of Common Stock in the case of Common Stock equivalents) by investors in connection with the Dilutive Issuance, less (y) the total number of shares of Common Stock purchased by such investor at the closing of the PIPE and any such additional shares of Common Stock acquired under this right. ParentCo must use commercially reasonable efforts to complete a financing transaction pursuant to which it would sell Common Stock or Common Stock equivalents resulting in gross proceeds of at least $5 million within 18 months of the closing of the PIPE (the “First Follow-On Financing”).

Burrill Capital Fund IV, LP (“Burrill”), Aisling Capital II, LP (“Aisling”), and Jerrold and Adam Grossman and their related entities (the “Grossman Group”), referred to as the “Lead Investors,” purchased 885,417, 458,334 and 114,584 shares of the Company’s common stock, respectively, for approximately $8,500,000, $4,400,000 and $1,100,000, respectively.   $262,740 in consideration paid by Aisling and the Grossman Group was in the form of secured promissory notes in lieu of cash.  The Company has agreed to reimburse the Lead Investors for their reasonable costs (including legal fees and expenses) up to a maximum of $70,000.   The Lead Investors, and the Company’s officers and directors, agreed not to sell, transfer or otherwise dispose of any of their Common Stock or securities convertible, exercisable or exchangeable for Common Stock for a period of 180 days following the closing of the PIPE.  In addition, with respect to any Lead Investor, until such time that such Lead Investor owns less than 50% of the shares of Common Stock that it received in the Merger in exchange for the shares of common stock that it owned immediately following the closing of the PIPE, if the Company proposes to offer any shares of its equity securities, or securities or debentures exchangeable for or convertible into additional shares of its equity securities for the purpose of financing its business (other than shares issued to employees, directors and consultants in the form of stock or options, shares issued upon exercise, exchange or conversion of any securities issued in the PIPE or outstanding as of the date of the Securities Purchase Agreement, shares issued pursuant to strategic agreements, shares offered to the public pursuant to an underwritten public offering, or other customary exclusions), the Company will offer such Lead Investor the right to participate in any such offering on the same terms and conditions otherwise available to investors therein, to the extent of an amount at least equal to their beneficial ownership percentage at the time of such offer.

In the event ParentCo is unable to raise at least $5 million in the First Follow-On Financing, then Burrill, Aisling and the Grossman Group will subscribe to purchase $1.5 million, $2.0 million and $0.5 million, respectively, which amounts will decline proportionately if ParentCo raises more than $1 million in addition to the amounts contributed by such Lead Investors.
 
 
F-13

 
 
In connection with the PIPE and the Merger, ParentCo agreed, pursuant to a registration rights agreement (the “Registration Rights Agreement”), to register on a registration statement (the “Investor Registration Statement”) the resale of the shares of Common Stock issued prior to the filing of the Investor Registration Statement, including the shares of Common Stock issued in the Merger in exchange for the shares of common stock issued in the PIPE and the shares of Common Stock owned by ParentCo’s pre-Merger stockholders, as well as the resale of the shares of Common Stock issuable upon exercise of the warrants issued to the placement agent in the Merger in exchange for the Placement Agent Warrants (as defined below).  The securities the resale of which is required to be registered on the Investor Registration Statement are referred to as the “Registrable Securities.”  To effect this registration, ParentCo is obligated to file the Investor Registration Statement with the SEC no later than 45 days following the completion of the Merger and the Investor Registration Statement shall be declared effective by the SEC within 180 days following the completion date of the Merger (240 days in case of a full review by the SEC).  If, among other events, the Investor Registration Statement is not filed within such 45-day period, is not declared effective within 180 days after the completion date of the Merger (240 days in the case of a full review by the SEC), or ceases to remain effective for more than 10 consecutive trading days or any 15 trading days during any 12-month period, ParentCo is required to pay in cash to the investors in the PIPE an amount per month equal to one percent of the investors’ subscription amount for Registrable Securities still held by the investors, until the Investor Registration Statement is filed, declared effective or continues to be effective (as the case may be).  This payment is subject to a maximum of (i) one percent of the investors’ subscription amount for Registrable Securities still held by the investors if ParentCo is diligently using its best efforts to have the Investor Registration Statement declared effective and the delays associated with the effectiveness of the Investor Registration Statement are the result of either continuing comments from or delays in reviewing by the SEC and (ii) ten percent of the investors’ subscription amount for Registrable Securities still held by the investors in all other cases.

If the SEC informs ParentCo that all of the securities required to be registered on the Investor Registration Statement cannot, as a result of the application of Rule 415 under the Securities Act, be registered for resale as a secondary offering on a single registration statement, ParentCo will use its commercially reasonable efforts to file amendments to the Initial Registration Statement as required by the SEC, covering the maximum number of such securities permitted to be registered by the SEC.   In such case, ParentCo will not be required to make payments in cash to the investors in the PIPE with respect to securities exceeding such maximum number if the registration statement is not declared effective within the time periods listed above.

ParentCo agreed to make such filings as are necessary to keep the Investor Registration Statement effective until the date on which all of the Registrable Securities have been sold or are saleable pursuant to Rule 144 (“Rule 144”) or its other subsections (or any successor thereto) under the Securities Act.  ParentCo is obligated to bear registration expenses (exclusive of transfer taxes, underwriters' discounts and commission) of all such registrations required.

The stockholders of the Company also have registration rights with respect to the shares of Common Stock issued in the Merger in exchange for shares of the Company’s common stock and shares of Common Stock issuable upon exercise of options they hold, pursuant to the Investors’ Rights Agreement.  They have agreed to waive their piggy back registration rights with respect to the Investor Registration Statement; however, they will be entitled to require the filing of a resale registration statement pursuant to the Investors’ Rights Agreement.

Under the terms of the Securities Purchase Agreement, the Company is obligated to cause securities to be delivered to non-affiliates without any restrictive legends if the resale of such securities has been registered, such securities have been sold pursuant to Rule 144 or, in certain circumstances, if such securities are eligible for sale under Rule 144.  If the Company fails to do so, it is obligated to pay to the investor, for each $1,000 of shares, $1 per trading day, increasing to $2 per trading day five trading days after such damages have begun to accrue, until unrestricted certificates are delivered.  In addition, if the Company fails to satisfy the current public information requirement under Rule 144(c), then the Company is obligated to pay to an investor, for any delay in or reduction of its ability to sell the securities, an amount equal to 1% of the aggregate subscription amount of such investor’s securities on the date of such current public information failure and on every 30th day thereafter (prorated for shorter periods) until the failure is cured or public information is no longer required for a Rule 144 sale.
 
 
F-14

 
 
Rodman & Renshaw, LLC (the “Placement Agent”) acted as the exclusive placement agent in connection with the PIPE.  The Company paid the Placement Agent a cash fee for its services equal to 7% of the aggregate offering price paid by each investor in the PIPE, other than with respect to certain investors.  As additional compensation, the Company issued the Placement Agent warrants (the “Placement Agent Warrants”) to purchase 87,865 shares of common stock of the Company.  The Placement Agent Warrants, which were exchanged for warrants of ParentCo in the Merger, are exercisable at $9.60 per share of Common Stock at any time beginning on August 11, 2012 and ending on February 13, 2017.  The Company also agreed to reimburse the Placement Agent for up to $100,000 of expenses it incurs in connection with the PIPE and to indemnify it against certain liabilities in connection with the PIPE.

On February 13, 2012, ParentCo entered into the a merger agreement (the “Merger Agreement”) with the Company and ADMA Acquisition Sub, Inc., a Delaware corporation (“Acquisition Sub”).  Upon closing of the Merger, Acquisition Sub was merged with and into the Company, and the Company, as the surviving corporation in the Merger, became a wholly-owned subsidiary of ParentCo.  ParentCo’s corporate name was changed to ADMA Biologics, Inc. and the name of the Company was changed to ADMA Plasma Biologics, Inc.

In connection with the Merger and pursuant to the terms of the Merger Agreement:

- all of the then issued and outstanding shares of the Company’s common stock, including the common stock issued in the PIPE and including the shares of the Company’s Series A preferred stock, which were converted into common stock immediately prior to and as part of the Merger, were automatically exchanged into 4,601,270 shares of common stock of ParentCo, par value $0.0001 per share (the “Common Stock”) at a 1:1 exchange ratio;

- all warrants, options and other rights to purchase or acquire shares of the Company’s common stock outstanding immediately prior to the Merger, including the Placement Agent Warrants and including the additional options granted to Adam S. Grossman under his new employment agreement, were converted into warrants, options or other rights, as the case may be, to purchase an aggregate of 383,380 shares of Common Stock at the same exercise prices; and

- 2,446,967 of the 2,500,000 shares of Common Stock held by the stockholders of ParentCo immediately prior to the Merger were canceled such that these stockholders now hold 53,033 shares of Common Stock, not including the 87,865 shares issuable upon exercise of the Placement Agent Warrants, held by an affiliate of one of such stockholders.

Immediately prior to the Merger and the transactions described above, (i) 3,386,454 shares of Series A Preferred Stock of the Company were converted into 11,243,748 shares of the Company’s common stock after giving effect to cumulative anti-dilution adjustments and accrued dividends, and 4,835,224 shares of the Company’s Series A Preferred Stock issued in December 2011 upon the conversion of convertible notes were converted into an equal number of shares of the Company’s common stock and (ii) the shares of common stock of the Company were reverse split at a ratio of 1-for-6.8 (the “Reverse Split”).  The consolidated financial statements were adjusted to give retroactive effect to the Reverse Split.
 
 
F-15

 
 
As part of the Merger, ParentCo assumed certain of the Company’s obligations under an investors’ rights agreement, dated July 17, 2007, by and among the Company and its stockholders (the “Investors’ Rights Agreement”), assumed the Company’s obligations under the Securities Purchase Agreement, and assumed the Company’s 2007 Employee Stock Option Plan.

After an increase in authorized shares under the 2007 Plan in connection with the Merger, the Company currently has options to purchase 295,515 shares of Common Stock issued and outstanding under the 2007 Plan and has reserved for future issuance under the 2007 Plan an additional 265,685 shares of Common Stock.

For accounting purposes, the Merger was accounted for as a reverse acquisition, with the Company as the accounting acquiror (legal acquiree) and ParentCo as the accounting acquiree (legal acquiror), effectively a recapitalization of the Company.

On February 13, 2012, the Company entered into a new employment agreement with its President and Chief Executive Officer, Adam S. Grossman, which has an initial term of three (3) years, with automatic three (3) year renewal periods unless notice is provided 90 days in advance.  The employment agreement provides that Mr. Grossman (i) will initially be paid $350,000 annually beginning on the date on which the Merger closed (the “Effective Date”); (ii) is eligible for an annual cash bonus, the target of which is $100,000, based upon the attainment of certain performance objectives mutually agreed to by the Board of Directors and Mr. Grossman;  (iii) was to be granted on the Effective Date options to purchase shares of Common Stock representing 4% of the Company’s equity on a fully diluted basis (options to purchase 212,134 shares of Common Stock at an exercise price of $9.60 were granted pursuant to this provision) and (iv) is eligible to participate in the Company's standard benefits package.  All options granted to Mr. Grossman were issued under the Company’s stock option plan and vest over a four year period, with 25% of the options vesting on the Effective Date, and the remaining 75% vesting in equal monthly installments over the following 48 months of continued employment (full vesting on the fourth anniversary of the Effective Date), subject to accelerated vesting (i) upon a “change of control” (as defined in the agreement) of the Company of all options if Mr. Grossman is terminated by the Company or its successor for any reason other than cause or by Mr. Grossman for “good reason” (as defined in the agreement) immediately preceding or within two years thereafter and (ii) of that portion of the options that would have vested over the one year period following the date of termination upon a termination of employment by the Company without cause or by Mr. Grossman for good reason or as a result of death or disability.  Mr. Grossman also received a bonus in connection with his 2011 performance, including in connection with the PIPE and Merger, of $50,000 on the date on which the Merger closed.  The Company is obligated to reimburse Mr. Grossman for up to $10,000 in legal expenses incurred in connection with the employment agreement.
 
F-16